DF1001 + sacituzumab govitecan-hziy

DF1001 + sacituzumab govitecan-hziy is a **combination regimen** under investigation for cancer treatment, composed of DF1001, a tri-specific natural killer (NK) cell engager therapy targeting HER2, and sacituzumab govitecan-hziy, an antibody-drug conjugate targeting Trop-2 and delivering SN-38, a topoisomerase I inhibitor. DF1001 stimulates NK, γδ T, and CD8+ T cell activation via HER2-targeted engagement, driving immune responses against tumor cells[1][5][7]. Sacituzumab govitecan-hziy binds Trop-2–expressing cancer cells and selectively releases SN-38 to induce DNA damage and cell death[2][4]. This combination modality integrates **immunotherapy** and **targeted cytotoxic chemotherapy**. Both are primarily developed for the treatment of solid tumors including metastatic breast cancer and other HER2-expressing cancers[1][2][5][7].

Brand names

Trodelvy

Other names

DF1001DF-1001DF 1001sacituzumab govitecansacituzumab govitecan-hziy